دورية أكاديمية
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
| العنوان: | Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study. |
|---|---|
| المؤلفون: | Longo F; Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, 28034, Spain., Jorge M; Hospital Álvaro Cunqueiro, Vigo (Pontevedra), 36213, Spain., Yaya R; Instituto Valenciano de Oncología (IVO), Valencia, 46009, Spain., Montes AF; Complexo Universitario Hospitalario de Ourense, 32005, Spain., Lago NM; Complejo Hospitalario Universitario, A Coruña, 15006, Spain., Brozos E; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela (La Coruña), 15706, Spain., Aparicio J; Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain., Quintero G; Hospital Universitario Lucus Augusti, Lugo, 27003, Spain., Ceballos E; Hospital San Pedro de Alcántara, Cáceres, 10003, Spain., Buxó E; Hospital Quirón Salud, Barcelona, 08023, Spain., Lopez AM; Hospital Universitario de Burgos, 09006, Spain., Pellón ML; Complexo Universitario Hospitalario de El Ferrol (La Coruña), 15405, Spain., Molina R; Hospital Universitario Príncipe de Asturias, Alcalá de Henares (Madrid), 28805, Spain., Diaz-Paniagua L; Hospital Universitario de Getafe (Madrid), 28905, Spain., Cerdà P; Centro Médico Teknon, Barcelona, 08022, Spain., Leiva PL; Complejo Hospitalario de Jaén, 23007, Spain., Carnicero AM; Hospital de San Pedro, Logroño, 26006, Spain., Cousillas A; Complexo Universitario Hospitalario de Pontevedra, 36071, Spain., Paris L; Centro Oncológico de Galicia, La Coruña, 15009, Spain., García-Paredes B; Hospital Clínico San Carlos, Madrid, 28040, Spain., Romero C; Hospital POVISA, Vigo (Pontevedra), 36201, Spain., Ortega M; Department of Medical, Lilly, Madrid, 28108, Spain., Molero A; Department of Medical, Lilly, Madrid, 28108, Spain., la Torre S; Department of Medical, Lilly, Madrid, 28108, Spain., Jen MH; European Statistics Group, Lilly, Surrey, GU206PH, UK., Díaz-Cerezo S; Department of Medical, Lilly, Madrid, 28108, Spain. |
| المصدر: | Future oncology (London, England) [Future Oncol] 2021 May; Vol. 17 (14), pp. 1777-1791. Date of Electronic Publication: 2021 Feb 16. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine Ltd., c2005- |
| مواضيع طبية MeSH: | Adenocarcinoma/*therapy , Antibodies, Monoclonal, Humanized/*administration & dosage , Paclitaxel/*administration & dosage , Stomach Neoplasms/*therapy, Adenocarcinoma/diagnosis ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/statistics & numerical data ; Esophagogastric Junction/pathology ; Esophagogastric Junction/surgery ; Female ; Gastrectomy ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy/methods ; Neoadjuvant Therapy/statistics & numerical data ; Paclitaxel/adverse effects ; Progression-Free Survival ; Retrospective Studies ; Spain/epidemiology ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Ramucirumab |
| مستخلص: | Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4-4.3) and 7.4 (95% CI: 6.4-8.9) in combination regimen and 2.0 (1.1-2.8) and 4.3 (95% CI: 1.9-7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials. |
| معلومات مُعتمدة: | Eli Lilly and Company |
| فهرسة مساهمة: | Keywords: effectiveness; gastric cancer/GEJ adenocarcinoma; ramucirumab; real-world data; treatment patterns |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) P88XT4IS4D (Paclitaxel) |
| تواريخ الأحداث: | Date Created: 20210216 Date Completed: 20211108 Latest Revision: 20231213 |
| رمز التحديث: | 20240628 |
| DOI: | 10.2217/fon-2020-1216 |
| PMID: | 33590772 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8301 |
|---|---|
| DOI: | 10.2217/fon-2020-1216 |